Alvotech (ALVO – Research Report) received a Hold rating and a price target from Citi analyst Andrew Baum today. The company’s shares closed yesterday at $8.85.
According to TipRanks, Baum is a 4-star analyst with an average return of 7.4% and a 63.81% success rate. Baum covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Alvotech, and Eli Lilly & Co.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alvotech with a $14.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
ALVO market cap is currently $2.37B and has a P/E ratio of -5.34.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alvotech (ALVO) Company Description:
Oaktree Acquisition Corp II is a blank check company.
Read More on ALVO:
- Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
- Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland
- Alvotech, Kashiv Biosciences enters exclusive licensing agreement for ADL018
- Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
- Alvotech says Fuji Pharma Co receives marketing approval for AVT04
